Quick Answer
LIGAND PHARMACEUTICALS INC reported Revenue (ASC 606) of $268.09 million for fiscal year 2025.
LIGAND PHARMACEUTICALS INC Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $268.09M | +60.4% |
| 2024 | $167.13M | +27.3% |
| 2023 | $131.31M | -33.1% |
| 2022 | $196.25M | -18.8% |
| 2021 | $241.54M | +47.7% |
| 2020 | $163.56M | +36.0% |
| 2019 | $120.28M | -52.2% |
| 2018 | $251.45M | +78.2% |
| 2017 | $141.10M | +29.5% |
| 2016 | $108.97M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $115.46M | +122.8% | +142.4% |
| June 30, 2025 | $47.63M | +14.7% | +5.1% |
| March 31, 2025 | $45.33M | +46.3% | -12.5% |
| September 30, 2024 | $51.81M | +57.6% | +24.8% |
| June 30, 2024 | $41.53M | +57.5% | +34.1% |
| March 31, 2024 | $30.98M | -29.6% | -5.8% |
| September 30, 2023 | $32.87M | -44.5% | +24.7% |
| June 30, 2023 | $26.37M | -47.4% | -40.0% |
- LIGAND PHARMACEUTICALS INC showed an increase of +60.4% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2016–2025 period, LIGAND PHARMACEUTICALS INC’s revenue (asc 606) has grown by 146.0% (from $108.97 million to $268.09 million).
- The most recent figure is from LIGAND PHARMACEUTICALS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: